| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Eric J. Topol | Q5387640 |
| P2093 | author name string | Lefkovits J | |
| Almony GT | |||
| P2860 | cites work | An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 |
| Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors | Q28294390 | ||
| Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction | Q28361743 | ||
| Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides | Q28619497 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states | Q33449857 | ||
| Thrombocytopenia Found Uncommonly During Heparin Therapy | Q33472988 | ||
| Heparin-associated thrombocytopenia: a comparison of three heparin preparations | Q33483421 | ||
| Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study | Q33493712 | ||
| Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients | Q33501249 | ||
| Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence | Q33555966 | ||
| Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial | Q33611581 | ||
| Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. | Q33856848 | ||
| Mechanism of action of thrombin on platelets | Q34017961 | ||
| Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty | Q34336722 | ||
| Aspirin as an antiplatelet drug | Q34338650 | ||
| The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials | Q34403671 | ||
| A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group | Q34540010 | ||
| Pharmacology of ticlopidine: a review | Q38664047 | ||
| Development of hirudin as an antithrombotic agent | Q38735170 | ||
| ??? | Q56638593 | ||
| Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction | Q40800107 | ||
| Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency | Q41123928 | ||
| Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) | Q43810060 | ||
| The effect of warfarin on mortality and reinfarction after myocardial infarction | Q44339433 | ||
| Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction | Q45083112 | ||
| Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study | Q45338175 | ||
| Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. | Q45899877 | ||
| The effects of long-term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction | Q46103667 | ||
| A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. | Q53985201 | ||
| Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers | Q67573953 | ||
| A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group | Q67987020 | ||
| A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke | Q68016827 | ||
| Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin | Q68577413 | ||
| The interaction of platelet factor four and glycosaminoglycans | Q68936529 | ||
| A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction | Q69175486 | ||
| Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator | Q69194179 | ||
| Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis | Q69224498 | ||
| Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction | Q69421691 | ||
| Heparin-induced thrombocytopenia | Q69505793 | ||
| Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N alpha-acetyl-hirudin45-65 | Q69721004 | ||
| Intracoronary prostacyclin in evolving acute myocardial infarction | Q69894952 | ||
| Thrombin/antithrombin-III complex level as early predictor of reocclusion after successful thrombolysis | Q69920192 | ||
| Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease | Q70168675 | ||
| A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction | Q70256379 | ||
| Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man | Q70314139 | ||
| Selective thrombin inhibitors: the next generation of anticoagulants | Q70503160 | ||
| Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris | Q70625383 | ||
| Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study | Q70709335 | ||
| Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography | Q71346656 | ||
| Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography | Q71756030 | ||
| Principles of platelet inhibitor therapy--where we stood in 1993 | Q71998652 | ||
| Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association | Q72285055 | ||
| Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association | Q72285059 | ||
| A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial | Q72332452 | ||
| Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial | Q72344112 | ||
| Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis | Q72344184 | ||
| Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy | Q72352884 | ||
| Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty | Q72677352 | ||
| Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group | Q72708506 | ||
| Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial | Q72711397 | ||
| Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators | Q72711401 | ||
| Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus | Q72786073 | ||
| AN ASSESSMENT OF LONG-TERM ANTICOAGULANT ADMINISTRATION AFTER CARDIAC INFARCTION. SECOND REPORT OF THE WORKING PARTY ON ANTICOAGULANT THERAPY IN CORONARY THROMBOSIS TO THE MEDICAL RESEARCH COUNCIL | Q76894478 | ||
| P433 | issue | 5 | |
| P921 | main subject | anticoagulant | Q215118 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 357-365 | |
| P577 | publication date | 1996-05-01 | |
| P1433 | published in | Clinical Cardiology | Q4502312 |
| P1476 | title | Antiplatelet and anticoagulant use after myocardial infarction | |
| P478 | volume | 19 |
| Q33500262 | Clinical pharmacology of eptifibatide |
| Q39453641 | Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy |
| Q42600559 | Introducers and protective sleeves may increase thrombogenicity of pulmonary artery catheters |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q40601689 | Molecular biology and gene transfer in atherosclerosis in the stenting era. |
| Q41195312 | Pharmacologic therapies after myocardial infarction. |
| Q34282877 | Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors |
| Q34074021 | Redefining medical treatment in the management of unstable angina |
| Q28211998 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice |
| Q33546230 | Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors |
| Q28181359 | The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study |
| Q52682792 | The predictive utility of the plant phylogeny in identifying sources of cardiovascular drugs. |
| Q33754183 | Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States |
| Q41589794 | Unmet therapeutic needs in the management of acute ischemia |
| Q28196407 | What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? |
Search more.